Leads and Contacts--June 2007
This article was originally published in RPM Report
Executive Summary
Key figures behind the June RPM features.
You may also be interested in...
No Sale: The Democratic Congress Tries to Roll Back Enrollment in Medicare Advantage
Price negotiation has stalled, but the Democratic Congress still wants to put its mark on Medicare Part D. There are plenty of levers to pull that could subtly but profoundly reshape the evolution of this critical new pharma market. One example: cracking down on marketing "abuses" by private Medicare plans.
Getting the Bugs Out of Antibiotic R&D: Commercial Implications of a Higher Regulatory Hurdle
It's a gloomy time for antibiotic R&D: higher regulatory hurdles and commercial challenges have forced many companies to leave the market. But a few major players and boutique firms remain committed to the field. What do they see that the rest of the industry is overlooking?
Rethinking Alzheimer's: Mapping Out an Approval Process
Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.